Table 2.
The difference of PDL1 expression by immunohistochemistry (IHC) according to clinical characteristics.
| (A) Gender (Male vs Female), p=1.000 | |||
|---|---|---|---|
| PDL1 IHC | |||
| Gender | Positive | Negative | Total |
| Male | 4 | 14 | 18 |
| Female | 3 | 11 | 14 |
| Total | 7 | 25 | 32 |
| (B) Primary site (Foregut vs Midgut vs Hindgut), p=1.000 | |||
| PDL1 IHC | |||
| Primary | Positive | Negative | Total |
| Foregut | 5 | 19 | 24 |
| Hindgut | 2 | 6 | 8 |
| Total | 7 | 25 | 32 |
| (C) WHO classification (Grade II vs Grade III), p=0.008 | |||
| PDL1 IHC | |||
| WHO | Positive | Negative | Total |
| Grade II | 0 | 15 | 15 |
| Grade III | 7 | 10 | 17 |
| Total | 7 | 25 | 32 |
| (D) Number of metastatic sites (1 vs 2≤), p=0.719 | |||
| PDL1 IHC | |||
| Metastatic sites | Positive | Negative | Total |
| 1 | 2 | 9 | 11 |
| 2≤ | 5 | 16 | 21 |
| Total | 7 | 25 | 32 |